Search This Blog

Monday, December 9, 2024

NFL, Justice Department urge Congress to take action on threat from drones

 The National Football League, the Justice Department, the FBI and other agencies will call on Congress on Tuesday to expand U.S. government authority to detect and destroy drones that could pose security threats over stadiums and other locations.

Congress has debated for years expanding authority amid growing safety concerns.

"The time to act to keep fans safe is now," NFL security chief Cathy Lanier will tell a U.S. House of Representatives subcommittee on Tuesday. According to Lanier's written testimony, rogue drone flights into the restricted air space above stadiums during NFL games rose to 2,845 in 2023 from 2,537 in 2022.

Drone flights are prohibited up to 3,000 feet (914 m) before major U.S. sporting events in a three-mile radius of stadiums.

The White House and sports leagues since 2022 have been pushing for expanded authority to detect threatening drones, with the NFL, Major League Baseball and other leagues warning previously that without expanded authority, airports and sporting events "are at substantial risk from malicious and unauthorized (drone) operation."

Congress in 2018 expanded the power of the Justice Department and Homeland Security to disable or destroy threatening drones, but officials say they need new authority.

Legislation would expand federal coverage for airports and critical infrastructure like power plants, oil refineries or chemical facilities and high-risk prisoner transports. It would also allow use of expanded counter-drone authorities by state and local law enforcement. Owners or operators of airports or critical infrastructure could also use federally vetted drone-detection capabilities.

"Gaps in legal authorities leave sensitive federal facilities, such as CIA headquarters, vulnerable to both intelligence collection by foreign states and physical attacks by hostile actors," said joint written testimony from the FBI and Justice Department. "We also need to allow critical infrastructure operators to take steps to protect their own facilities and assets."

DHS said in written testimony that in a recent six-week period there were more than 6,900 drone flights within close proximity of the Southwest border, saying "the use of drones for illicit cross border activity is not only widespread, but highly organized."

https://www.yahoo.com/news/nfl-justice-department-urge-congress-234331659.html

Mysterious drone clusters witnessed across Philadelphia region as FBI continues investigation

 People from all across the Delaware Valley and up into northern New Jersey have reported seeing clusters of drones in the sky over the past several weeks.

Numerous reports were sent to Action News about flying objects in Media and Broomall in Delaware County, as well as in Philadelphia's Mayfair section and in Cherry Hill, Camden County.

We've been asking local and federal officials if they can offer an explanation. Simply put, so far, the answer is no.

We spoke with Maureen Rush who is a 45-year law enforcement veteran and president of the Philadelphia Police Foundation. She says it's important to note that many of the sightings include commercial-grade drones, some as large as small airplanes, not the kinds used by hobbyists.

"My other concern is that there are multiple drone sightings. They're almost in a flock. If they were geese, they'd be in a flock, and that's what's really unnerving for people," she said.

Over in New Jersey, Governor Phil Murphy has publicly stated that this drone activity does not pose a public safety concern, but he has offered little else regarding an explanation.

And State Senator Doug Steinhardt says that's simply not good enough.

"I'd be happy with an explanation that we've looked at it, and we don't have information, or for law enforcement to say it's an ongoing something or other, you know, and that's as much as we can tell you, but we're not even getting that which is unfortunate," said Steinhardt.

And Steinhardt says he's not just speaking as a lawmaker, he's speaking as a witness.

"I walked out of my front porch last night and saw it would look like drone activity to me. I mean, I've seen airplanes cross the sky before and this wasn't that," he says.

Steinhardt has since sent letters to fellow lawmakers, including Governor Murphy, requesting they convene a bipartisan panel to discuss the situation.

The FBI is involved in the investigation.


https://6abc.com/post/large-drones-spotted-philadelphia-area-fbi-investigates-mysterious-drone-sightings-new-jersey/15630194/

Jefferies picks Metagenomi, Structure

 There’s been something of a sea change in the economic outlook for 2025, in the aftermath of last month’s election. The prospect of a second Trump administration, with his known preference for deregulation and tax cuts, has market watchers expecting a growth-friendly environment.

Desh Peramunetilleke, Jefferies’ Global Head of Quantitative Strategy, notes that reduced regulation, combined with the potential for lower corporate tax rates, could significantly boost the biotech sector, with smaller biotech stocks poised to benefit the most.

“Our recent analysis concluded with a near-term preference for smaller-cap biotech names in the US… Trump’s win brings new market dynamics into play. Firstly, his policies concerning taxation and government regulation imply a more risk-on environment, encouraging investments and M&A activity. This is conducive for rerating of the smaller biotech names,” Peramunetilleke explained.

Following his lead, Jefferies stock analysts have picked two small biotech stocks with strong upside – including one with a potential gain of nearly 1,000%.


Metagenomi (MGX)

The first Jefferies pick we’re looking at is Metagenomi, a biotech innovator unlocking the potential of gene editing through the power of metagenomics. This approach focuses on identifying microbial genetic systems shaped by nature and adapting their enzymes into precise tools for addressing various diseases. By leveraging the vast genetic diversity found in nature, Metagenomi aims to develop therapeutic solutions that could contribute to meaningful advancements in modern medicine.

The company’s flagship candidate, MGX-001, is a novel therapeutic agent targeting hemophilia A (hemA). Last quarter, Metagenomi announced an important achievement, reaching durable Factor VIII activity levels over a one-year period in an NHP (non-human primate) study. The company has gone on to initiate IND-enabling activities for MGX-001 as a regulatory step toward moving the program to the human clinical trial stage.

But Metagenomi isn’t stopping there. Through a partnership with Ionis Pharmaceuticals, the company is integrating RNA-targeted therapeutics with its gene-editing systems. This collaboration focuses on cardiometabolic development programs, initially targeting four conditions, including transthyretin amyloidosis (TTR) and refractory hypertension (AGT). Currently in the lead optimization phase, these programs have demonstrated proof-of-concept in rodent models. Looking ahead, Metagenomi plans to nominate one to two development candidates by 2025.

With early clinical progress and a share price of just $1.85, Jefferies analyst Maury Raycroft believes MGX shares represent a high-potential opportunity.

“We continue to view MGX stock as undervalued given: 1) derisking 1-yr NHP data, which sets the stage for durable FVIII expression for hemA; 2) broad platform play with multiple genome editing capabilities along with in-house GMP manuf capabilities — could facilitate multiple BD deals with initial PoC studies; 3) IONS-partnered cardiometabolic programs advancing toward DC nomination in 2025 with rodent POC achieved,” Raycroft noted.

“Though first human testing may not begin until 2026 in lead hemA and PH1 programs, animal PoC data in >2024 across their portfolio along with potential BD deals could further strengthen the platform, potentially driving the shares higher given broad applicability and valuation at a discount,” the analyst added.

So, how high could this go? Raycroft gives MGX a Buy rating, with a price target of $21, suggesting a remarkable 1,035% upside potential. (To watch Raycroft’s track record, click here)

Like Raycroft, other Wall Street analysts are optimistic about this biotech’s prospects. With 5 Buys assigned in the last three months, the message is clear: MGX is a Strong Buy. Should the $17.50 average price target be met, a twelve-month gain of ~846% could be in the cards. 


Structure Therapeutics (GPCR)

Next on Jefferies’ radar is Structure Therapeutics, a clinical-stage biopharmaceutical company dedicated to developing new treatments for chronic conditions, particularly metabolic and pulmonary diseases that have, in the jargon, ‘high unmet medical needs.’

Structure’s technology is based on G-protein coupled receptors (GPCRs), which make up the largest family of human membrane proteins. GPCRs are involved in most aspects of human physiology, and more than 100 of these proteins are acted on by some 475 drugs on the market. While that sounds like a lot, there is still a large addressable market here – more than 220 of these proteins remain available as targets for clinical research.

The company’s leading drug candidate is GSBR-1290, an orally-dosed small molecule agonist of the glucagon-like-peptide-1 (GLP-1) receptor. GLP-1 has been validated as a useful drug target in the treatment of both obesity as a metabolic condition and type 2 diabetes mellitus. The drug was developed on Structure’s platform as a biased GPCR agonist, selectively activating the G-protein signal pathway. GSBR-1290 is currently under investigation in clinical trials as a treatment for obesity.

These trials have advanced to the Phase 2 stage, and in June, the company released a set of positive data from the earlier Phase 2a study. Last month, Structure announced that the follow-up trial, the Phase 2b ACCESS study, had begun dosing patients.

Beyond GSBR-1290, Structure is progressing with the development of an orally administered small molecule amylin receptor agonist for obesity treatment. The company aims to finalize a development candidate by year-end.

Covering this company for Jefferies, analyst Roger Song notes the success – and the future potential – of GSBR-1290, writing of the program: “OW data reaffirms class leading efficacy of GSBR1290, with PK/PD modeling suggest long-term WL in line with orfo/ sema supporting ‘1290 into Ph2b in 4Q24… With promising Ph2a 12W data on hand, and Ph2b 36W data expected in 4Q25, we see ‘1290 is leading new-gen small molecule incretin space, and can potentially set the new bars if we can see directionally higher WL with higher doses and improved GI tolerability with 120mg dose.”

Song has also taken note of the amylin program and is optimistic about the company’s ability to develop a competitive drug candidate: “Amylin program excitement continues, with first DC to announce YE24 and multiple others in planning. Comp data from AZD5004 and AZD6234 both underwhelming, further solidifying GPCR leading position with robust pipeline.”

The potential inherent in these two programs led Song to rate Structure shares as a Buy, while his $79 price target points toward a one-year upside potential of ~137%. (To watch Song’s track record, click here)

All in all, Structure has picked up 9 unanimously positive analyst reviews, supporting a Strong Buy consensus rating. The stock is currently trading for $33.35, and its $88.56 average price target implies a gain of 165% in the next 12 months. 


https://finance.yahoo.com/news/jefferies-predicts-1000-surge-2-110518004.html

Another system faces lawsuit over patient information allegedly shared with Facebook

 Philadelphia-based Jefferson Health is the latest system to face a class action lawsuit over allegations that it allowed Facebook's third-party tracking technology to access private patient information, The Philadelphia Inquirer reported Dec. 9.

The lawsuit alleges that Meta, Facebook's parent company, had access to information about when patients logged into patient portals, when they scheduled appointments and what was put into appointment forms, and data on what providers, specialists and medical condition pages they visited on Jefferson's website. Patients did not give permission for information to be shared and were not notified of what information would be shared, according to the lawsuit. 

Members of the class action said they suspected their information had been shared after they started seeing Facebook ads related to their medical conditions.

Jefferson, in legal filings, denied using Meta Pixel on its patient portals and said that third-party tracking software is used on public-facing websites, but not private medical information. 

"The deployment of these tools enabled Defendant to measure browsing traffic, ensure website optimization, and increase awareness of the services offered by Jefferson Health to the community at large," the system said in court filings. Jefferson declined to comment on pending litigation, it told the Inquirer.

Jefferson Health is just the latest system to face lawsuits around Meta Pixel.

In September, a Georgia federal judge dismissed the class action lawsuit, which claimed Piedmont unlawfully shared patient data by using Meta Pixel on its website and patient portal. The lawsuit argued that Meta Pixel transmitted patient information to Facebook without consent, but the judge ruled that the complaint failed to demonstrate actual damages. In April, a lawsuit against Oakland, Calif.-based Kaiser Permanente alleged that trackers collected and transmitted patients' names, internet addresses and search terms to tech companies such as Google, X (formerly Twitter) and Microsoft's Bing. Another lawsuit against the Blue Cross Blue Shield Association also that a website for the federal employees’ health plan sent data to TikTok and other tech companies.

Systems have begun to remove pixel tracking technology from their websites in the wake of the recent lawsuits. 

Bloomberg analysis found that trackers from Meta Platforms' Facebook were able to access sensitive information such as dates of birth and phone numbers, and partial Social Security numbers on Cigna Group's pharmacy unit website and UnitedHealth Group's pharmacy benefit division website. A Meta spokesperson told Bloomberg that advertisers are not supposed to transmit sensitive personal information via the company's tools and that Meta's system is engineered to filter out such data when it is detected.


The Federal Trade Commission has fined telehealth companies for sharing user data, and HHS issued guidance that online trackers could violate federal health privacy rules — however, a Texas court ruling limited HHS' ability to penalize healthcare companies for using trackers.

https://www.beckershospitalreview.com/legal-regulatory-issues/another-system-faces-lawsuit-over-patient-information-allegedly-shared-with-facebook.html

Experts torn on Ozempic microdosing

 There is growing interest in microdosing weight loss drugs like Ozempic, with some users reporting positive results despite limited evidence and mixed opinions from experts, The New York Times reported Dec. 5. 

Microdosing involves taking smaller doses of the drug than typically prescribed to minimize side effects such as nausea and vomiting, which some users find intolerable at standard doses. 

Erica Liebman, a psychologist in Philadelphia, told the news outlet she turned to microdosing after hearing about it from a health influencer who promotes the practice for various health issues, including weight loss. Ms. Liebman and others have turned to social media to share experiences of microdosing, claiming benefits such as reduced hunger and easier weight management. 

Experts are divided on the subject, however. While some suggest that even small doses of Ozempic could suppress appetite, there is little scientific data to support claims that microdosing leads to significant weight loss, according to the report. 

Andrew Kraftson, MD, a clinical endocrinologist at Ann Arbor-based Michigan Medicine, said microdosing can be risky without medical guidance, though it might not pose immediate danger in small amounts. 

https://www.beckershospitalreview.com/pharmacy/experts-torn-on-ozempic-microdosing.html

Who is Luigi Mangione?



Police arrested a suspect Monday in the brazen Manhattan killing of UnitedHealthcare's CEO after a quick-thinking McDonald’s employee in Pennsylvania alerted authorities to a customer who was found with a weapon, mask and writings linking him to the ambush.



Here's the latest:



A 26-year-old man, Luigi Nicholas Mangione, was arrested in Pennsylvania, suspected of murdering UnitedHealth CEO Brian Thompson with a ghost gun.
The suspect was found with a weapon, fraudulent IDs, and clothing matching those seen in surveillance footage linked to the crime.
Investigators suggest the suspect may have had "ill will toward corporate America," as indicated by a handwritten document found in his possession.

The chance sighting at the restaurant in Altoona led to a dramatic break in a challenging but fast-moving investigation that had captivated the public in the five days since the shooting that shook the health insurance industry.

The suspect, identified by police as 26-year-old Luigi Nicholas Mangione, had a gun believed to be the one used in last Wednesday’s shooting of Brian Thompson, as well as writings suggesting anger with corporate America, police said.

Mangione was taken into custody about 9:15 a.m. after police got a tip that he was eating at a McDonald’s in Altoona, Pennsylvania, police said.

"He is believed to be our person of interest in the brazen, targeted murder of Brian Thompson,” NYPD Commissioner Jessica Tisch said.

Mangione had clothing and a mask similar to those worn by the shooter and a fraudulent New Jersey ID matching one the suspect used to check into a New York City hostel before the shooting, Tisch said.

NYPD Chief of Detectives Joseph Kenny said Mangione was born and raised in Maryland, has ties to San Francisco and a last known address in Honolulu, Hawaii. A message left Monday with a Philadelphia-area phone number connected to Mangione was not immediately returned.

He was being held in Pennsylvania on gun charges and eventually will be extradited to New York to face charges in connection with Thompson’s death, Kenny said.

Police found a three-page document with writings suggesting that Mangione had “ill will toward corporate America,” Kenny said.

The handwritten document “speaks to both his motivation and mindset,” Tisch said.

Mangione had a ghost gun, a type of weapon that can be assembled at home from parts without a serial number, making them difficult to trace, investigators said.

“As of right now the information we’re getting from Altoona is that the gun appears to be a ghost gun that may have been made on a 3D printer, capable of firing a 9 mm round,” Kenny said.

Officers questioned Mangione, who was acting suspiciously and carrying multiple fraudulent IDs, as well as a U.S. passport, Tisch said. Officers found a suppressor, “both consistent with the weapon used in the murder,” the commissioner said.

NYPD detectives and staff from the Manhattan district attorney’s office traveled to Altoona to interview Mangione, Kenny said.

Thompson, 50, was killed last Wednesday as he walked alone to a hotel, where UnitedHealthcare’s parent company, UnitedHealth Group, was holding its annual investor conference, police said.

UnitedHealth Group thanked law enforcement in a statement Monday. “Our hope is that today’s apprehension brings some relief to Brian’s family, friends, colleagues and the many others affected by this unspeakable tragedy,” a company spokesperson said.

The shooting shook U.S. businesses and the health insurance industry in particular, causing companies to rethink security plans and delete photos of executives from their websites.

The shooter appeared to be “lying in wait for several minutes” before approaching the executive from behind and opening fire, police said. He used a 9 mm pistol that police said resembled the guns farmers use to put down animals without causing a loud noise.

Mangione attended an elite Baltimore prep school, graduating as valedictorian in 2016, according to the school’s website. He went on to earn undergraduate and graduate degrees in computer science in 2020 from the University of Pennsylvania, a school spokesman said.

One of his cousins is a Maryland state legislator and his family bought a country club north of Baltimore in the 1980s. On Monday, police blocked off an entrance to the property, which public records link to the suspect's parents. A swarm of reporters and photographers gathered outside.

In the days since the shooting, police turned to the public for help by releasing a collection of nine photos and video — including footage of the attack, as well as images of the suspect at a Starbucks beforehand.

Photos taken in the lobby of a hostel on Manhattan’s Upper West Side showed the suspect grinning after removing his mask, police said.

On Monday, police credited news outlets for disseminating the images and the tipster for recognizing the suspect and calling authorities.

Investigators earlier suggested the gunman may have been a disgruntled employee or client of the insurer. Ammunition found near Thompson’s body bore the words “delay,” “deny” and “depose,” mimicking a phrase used by insurance industry critics.

The gunman concealed his identity with a mask during the shooting yet left a trail of evidence, including a backpack he ditched in Central Park, a cellphone found in a pedestrian plaza and a water bottle and protein bar wrapper that police say he bought at Starbucks minutes before the attack.

On Friday, police said the killer had left the city soon after the shooting. Retracing the gunman’s steps using surveillance video, investigators say the shooter rode into Central Park on a bicycle and emerged from the park without his backpack.

He then walked a couple blocks and got into a taxi, arriving at at the George Washington Bridge Bus Station, which is near the northern tip of Manhattan and offers commuter service to New Jersey and bus routes to Philadelphia, Boston and Washington, Kenny said.

The FBI announced late Friday that it was offering a $50,000 reward, adding to a reward of up to $10,000 that the NYPD offered.

Multiple law enforcement officials have identified Luigi Mangione as the man being questioned in the murder of UnitedHealthcare CEO Brian Thompson in New York City.


What we know so far




According to officials, the 26-year-old was born and raised in Maryland and has no prior arrest history in New York.

Mangione was allegedly spotted at a McDonald's in Altoona, Pennsylvania, on Monday, where a restaurant employee recognized him from images police have circulated.


Altoona police were called and took the man to a local precinct for questioning. The NYPD sent detectives to Pennsylvania to question the person taken into custody.

Mangione was arrested after he was found in possession of a ghost gun capable of firing a 9mm round, authorities said.

Mangione was found with a fake New Jersey driver's license, like the one the NYPD has said the suspect used to check in at a Manhattan hostel. Mangione had clothing and a mask similar to those worn by the shooter, according to NYPD Commissioner Jessica Tisch.

Altoona police also recovered a computer.

"It does seem that he had some ill will toward corporate America," NYPD Chief of Detectives Joseph Kenny said.

Citing a law enforcement official, The Associated Press reported that authorities also found a silencer and writings that appeared to be critical of the health insurance industry.

He was being held in Pennsylvania on gun charges and eventually will be extradited to New York to face charges in connection with Thompson’s death, Kenny said.
Ties to Maryland, California and Hawaii

According to Chief of Detectives Joe Kenny, Mangione has ties to both San Francisco, California, and Honolulu, Hawaii.

Mangione was valedictorian of the Class of 2016 at the Gilman School, an elite private all-boys school in Baltimore, Maryland. In his graduation speech, he talked about his classmates’ “incredible courage to explore the unknown and try new things.” He praised their collective inventiveness and pioneering mindset.

WBAL in Baltimore confirmed that Mangione was an alumnus and valedictorian of the school.


The Associated Press reports that Mangione comes from a prominent Maryland family. His grandfather Nick Mangione, who died in 2008, was a successful real estate developer. One of his best-known projects was Turf Valley Resort, a sprawling luxury retreat and conference center outside Baltimore that he purchased in 1978. The father of 10 children, Nick Mangione prepared his five sons — including Luigi Mangione’s father, Louis Mangione — to help manage the family business, according to a 2003 Washington Post report.

The Mangione family also purchased Hayfields Country Club north of Baltimore in 1986. On Monday, Baltimore County police officers blocked off an entrance to the property, which public records link to Luigi Mangione’s parents. A swarm of reporters and photographers gathered outside the entrance.

He is also the cousin of a Baltimore County delegate.

Luigi Mangione earned undergraduate and graduate degrees from the University of Pennsylvania.


His social media posts also suggest that he belonged to the fraternity Phi Kappa Psi. They also show him taking part in a 2019 program at Stanford University, and in photos with family and friends at the Jersey Shore and in Hawaii, San Diego, Puerto Rico, and other destinations.


KCRA in California reports that an apparent LinkedIn page for Luigi Mangione has biographical details that line up with that description.

Mangione's LinkedIn page said that he worked part-time as a head counselor teaching about artificial intelligence to “gifted high school students” at Stanford University during the summer of 2019.

That included leading a seven-member residential staff “in creating an inclusive, fun and stimulating residential community,” according to the social media page.

According to the program’s website, the pre-collegiate studies program hosts students from across the world.

“We can confirm that a person by the name of Luigi Mangione was employed as a head counselor under the Stanford Pre-Collegiate Studies program between May and September of 2019,” Stanford spokesperson Dee Mostofi told KCRA 3 in a statement.

The same LinkedIn page said Mangione has worked at Santa Monica-based TrueCar, Inc. for the past four years as a data engineer.

A TrueCar representative said the company generally doesn't comment on personnel matters but that it could confirm Mangione "has not been an employee of our company since 2023."

Representatives for the NYPD told KCRA they could not confirm details about Mangione's ties to California beyond what has already been announced or the authenticity of the LinkedIn page at this time.

https://www.wdsu.com/article/luigi-mangione-united-healthcare-ceo-shooting/63137969

So where are the articles complaining about Medicare and Obamacare insurance coverage denials?

 By Jack Hellner

Ever since the UnitedHealthCare CEO was killed, we see a lot of articles railing against denials by private health insurance companies. We even see some degenerate people claiming that health insurance executives deserve to get killed.

What we don’t see are articles talking about how many claims Medicare turns down because most of the media are advocates for government run health care for all. Facts don’t matter to the media when they are pushing an agenda.

Here is an article that shows how many claims Medicare initially turns down and how costly it is for medical providers to fight the denials.

Payer Denial Tactics — How to Confront a $20 Billion Problem

The high cost to health care providers to obtain reimbursement from insurers shows no signs of abating.

A recent report from the group purchasing and consulting organization Premier highlights the long-standing problem. It found that:

  • Hospitals and health systems spent an estimated $19.7 billion in 2022 trying to overturn denied claims.
  • Denied claims tended to be more prevalent for higher-cost treatments, with the average denial pegged to charges of $14,000 or more.
  • Nearly 15% of all claims submitted to private payers initially are denied, including many that were preapproved during the prior authorization process. Overall, 15.7% of Medicare Advantage and 13.9% of commercial claims were initially denied.
  • More than half of denied claims (54.3%) by payers ultimately were overturned but typically only after providers went through multiple rounds of costly appeals.

The High Cost of Reimbursement

The Premier findings track with the AHA's most recent survey that was conducted between December 2021 and February 2022. In that survey, 78% of hospitals reported that their experience with commercial payers was getting worse.

Moreover, 84% of respondents said the cost of complying with insurer policies was increasing and 95% of hospitals and health systems reported that their staffs were spending more time on prior approval processes. Respondents also said that 62% of prior authorization denials and 50% of initial claims denials that were appealed were overturned.

And here is an article about Obamacare denials while the media and other Democrats brag about how great it is.

Claims Denials and Appeals in ACA Marketplace Plans in 2021

In this brief, we analyze transparency data released by the Centers for Medicare and Medicaid Services (CMS) on claims denials and appeals for non-group qualified health plans (QHPs) offered on HealthCare.gov. Data were reported by insurers for the 2021 plan year and posted in a public use file in October 2022. We find that, across HealthCare.gov insurers with complete data, nearly 17% of in-network claims were denied in 2021. Insurer denial rates varied widely around this average, ranging from 2% to 49%.

If we want top see what the government believes on health care they should just see what Ezekiel Emanual, an architect of Obamacare, said:

Dr. Ezekiel Emanuel argues that the quality of human life begins to drop off by age 75, enough, he says, that he will opt out of medical treatments and let nature take its course.

I am 71 and I believe I am a better judge of my quality of life than some government bureaucrat.

While Democrats will never limit what lawyers can sue private insurers for, they are prevented from suing Medicare or Medicaid for punitive damages because they are government programs and sovereign immunity protects the government.

The goal for Democrats has always been to destroy private health insurance and Obamacare destroyed competition and massively escalated costs for everyone as they continue to lie that it makes health insurance more affordable.

On a personal note: My mother was 91 and broke her back. She was in massive pain, and I took her to the emergency room. They gave her morphine and other drugs and told me that I should take her home. They admitted that Medicare does everything they can to prevent admittance because if they are admitted for three days they are liable to nursing homes for coverage up to 100 days. 100% for the first twenty days and 80% for the next eighty days. They didn’t care about my mom’s health or the harm that would cause to my family. They cared about money.

Well, it took me eleven hours, but she was admitted for nine days and in the nursing home for around 50 days before she died.

I feel tremendously sorry for poor people who don’t have anyone there to advocate for them. My brother is a lawyer and I am a C.P.A. We know how to fight.

I would much rather negotiate with a private insurer than have the government control 100% of our health care.

https://www.americanthinker.com/blog/2024/12/so_where_are_the_articles_complaining_about_medicare_and_obamacare_insurance_coverage_denials.html